Use of real-world evidence for oncology clinical decision making in emerging economies
Despite RWE being a relatively nascent concept in emerging economies, we have seen evidence of increasing use over the past 5 years growing at 11% per year. That said, barriers specific to emerging economies need to be overcome through collaborative efforts, with regulatory agencies at the forefront. Regulatory engagement and sponsorship, RWE investments – both programmatic and one-off study sponsorships, and RWE training targeted at HCPs can harness the potential of RWE research in emerging economies.
Current scenario: Increasingly, real-world evidence (RWE) is being used to guide clinical decision making in oncology in emerging economies. However, there are several challenges associated with RWE use in emerging economies.
Future directive: The RWE challenges identified in this article can be addressed through regulatory engagement and sponsorship, RWE investments and RWE training targeted at healthcare professionals.
Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity.
Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.
Click for Source
